Tislelizumab combined with nab-paclitaxel, adriamycin and cyclophosphamide chemotherapy in neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study

被引：0
|
作者：
Zhang, G. [1 ]
He, Y. [1 ]
Luo, D. [1 ]
Zhang, X. [1 ]
Gao, B. [1 ]
Jiang, Y. [1 ]
Zhao, J. [1 ]
Guo, L. [1 ]
Xu, Y. [1 ]
机构：
[1] Army Specialty Med Ctr PLA, Dept Breast & Thyroid Surg, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
26TiP
引用
收藏
页码：S1414 / S1414
页数：1
相关论文
共 50 条
  • [41] Nab-paclitaxel maintenance therapy following carboplatin plus nab-paclitaxel combination therapy in chemotherapy naive patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial
    Nakao, Akira
    Uchino, Junji
    Igata, Fumiyasu
    On, Rintaro
    Ikeda, Takato
    Yatsugi, Hiroshi
    Hirano, Ryosuke
    Sasaki, Tomoya
    Tanimura, Keiko
    Imabayashi, Tatsuya
    Tamiya, Nobuyo
    Kaneko, Yoshiko
    Yamada, Tadaaki
    Nagata, Nobuhiko
    Watanabe, Kentaro
    Kishimoto, Junji
    Takayama, Koichi
    Fujita, Masaki
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 903 - 910
  • [42] Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
    Snider, Jessica N.
    Young, Robyn R.
    Schwartzberg, Lee Steven
    Allen, Jeffrey Warren
    Javed, Yasir Ahmed
    Jahanzeb, Mohammad
    Sachdev, Jasgit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study
    Recchia, Francesco
    Candeloro, Giampiero
    Desideri, Giovambattista
    Necozione, Stefano
    Recchia, Cornelia O. C.
    Cirulli, Vincenzo
    Rea, Silvio
    CANCER MEDICINE, 2012, 1 (01): : 89 - 95
  • [44] Neoadjuvant tislelizumab plus chemotherapy among patients with advanced ovarian cancer: A prospective, single-arm, phase II study
    Zhou, Jinhua
    Liu, Wei
    Huang, Yazhen
    Ding, Hongmei
    Chen, Youguo
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S298 - S299
  • [45] Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial
    Akira Nakao
    Junji Uchino
    Fumiyasu Igata
    Rintaro On
    Takato Ikeda
    Hiroshi Yatsugi
    Ryosuke Hirano
    Tomoya Sasaki
    Keiko Tanimura
    Tatsuya Imabayashi
    Nobuyo Tamiya
    Yoshiko Kaneko
    Tadaaki Yamada
    Nobuhiko Nagata
    Kentaro Watanabe
    Junji Kishimoto
    Koichi Takayama
    Masaki Fujita
    Investigational New Drugs, 2018, 36 : 903 - 910
  • [46] Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with locally advanced triple negative breast cancer
    Yuan, Y.
    Frankel, P.
    Li, M.
    Kruper, L.
    Jones, V.
    Treece, T.
    Waisman, J.
    Yim, J.
    Tumyan, L.
    Schmolze, D.
    Hurria, A.
    Yeon, C.
    Mortimer, J.
    Somlo, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [47] The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer-An open-label, single-arm, phase 2 trial
    Chen, Li
    Shao Zhimin
    Wang, Zhonghua
    Yang, Wentao
    Jiang, Yizhou
    Wu, Songyang
    Wu, Jiong
    Di, Genhong
    Liu, Guangyu
    Yu, Keda
    Fan, Lei
    Li, Junjie
    Hou, Yifeng
    Hu, Zhen
    Chen, Canming
    Huang, Xiaoyan
    Cao, Ayong
    Hu, Xin
    Zhu, Xiaoyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)
    Yan, Xiaolong
    Duan, Hongtao
    Ni, Yunfeng
    Zhou, Yongan
    Wang, Xiaoping
    Qi, Haini
    Gong, Li
    Liu, Honggang
    Tian, Feng
    Lu, Qiang
    Sun, Jianyong
    Yang, Ende
    Zhong, Daixing
    Wang, Tao
    Huang, Lijun
    Wang, Jian
    Wang, Chaoyang
    Wang, Yuanyong
    Wan, Zhiyi
    Lei, Jie
    Zhao, Jinbo
    Jiang, Tao
    INTERNATIONAL JOURNAL OF SURGERY, 2022, 103
  • [49] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [50] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Qin, Yan-ru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 340 - 340
12345